Hepatotoxicity induced in rats by chronic exposure to F–53B, an emerging replacement of perfluorooctane sulfonate (PFOS)
Environmental Pollution · 2024-04 · 346 · 123544
DOI: 10.1016/j.envpol.2024.123544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Pollution, 2024-04. Verfasst von Xiaohan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Occupational and Environmental Health, School of Public Health, Suzhou Medical College, Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Alkanesulfonic Acids, Fluorocarbons, Drug-Related Side Effects and Adverse Reactions, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
A plethora of studies have shown the prominent hepatotoxicity caused by perfluorooctane sulfonate (PFOS), yet the research on the causality of F-53 B (an alternative for PFOS) exposure and liver toxicity, especially in mammals, is largely limited. To investigate the effects that chronic exposure to F-53 B exert on livers, in the present study, male SD rats were administrated with F-53 B in a certain dose range (0, 1, 10, 100, 1000 μg/L, eight rats per group) for 6 months via drinking water and the hepatotoxicity resulted in was explored. We reported that chronic exposure to 100 and 1000 μg/L F-53 B induced remarkable histopathological changes in liver tissues such as distinct swollen cells and portal vein congestion. In addition, the increase of cytokines IL-6, IL-2, and IL-8 upon long-term administration of F-53 B demonstrated the high level of inflammation. Moreover, F-53 B exposure was revealed to disrupt the lipid metabolism in the rat livers, mainly manifesting as the upregulation of some proteins involved in lipid synthesis and degradation, including ACC, FASN, SREBP-1c as well as ACOX1. These findings provided new evidence for the adverse effects caused by chronic exposure to F-53 B in rodents. It is crucial for industries, regulatory agencies as well as the public to remain vigilant about the adverse health effects associated with the emerging PFOS substitutes such as F-53 B. Implementation of regular monitoring and risk assessments is of great importance to alleviate environmental concerns towards PFOS alternatives exposure, and furthermore, to minimize the latent health risks to the public health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Occupational and Environmental Health, School of Public Health, Suzhou Medical College, Soochow University, Suzhou, China.
- Department of Experimental Center, Suzhou Medical College, Soochow University, Suzhou, China.
- Department of Occupational and Environmental Health, School of Public Health, Suzhou Medical College, Soochow University, Suzhou, China. Electronic address: yunzhao@suda.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Zhang, Q., Wang, A., Shan, S., Wang, X., Wang, Y., Wan, J., Ning, P., Hong, C., Tian, H., & Zhao, Y. (2024). Hepatotoxicity induced in rats by chronic exposure to F–53B, an emerging replacement of perfluorooctane sulfonate (PFOS). Environmental Pollution, 346, 123544. https://doi.org/10.1016/j.envpol.2024.123544
Vancouver
Li X, Zhang Q, Wang A, Shan S, Wang X, Wang Y, et al. Hepatotoxicity induced in rats by chronic exposure to F–53B, an emerging replacement of perfluorooctane sulfonate (PFOS). Environmental Pollution. 2024;346:123544. doi:10.1016/j.envpol.2024.123544
BibTeX
@article{Li2024,
author = {Li, Xiaohan and Zhang, Qian and Wang, Aiqing and Shan, Shan and Wang, Xueying and Wang, Yarong and Wan, Jianmei and Ning, Ping and Hong, Chengjiao and Tian, Hailin and Zhao, Yun},
title = {Hepatotoxicity induced in rats by chronic exposure to F–53B, an emerging replacement of perfluorooctane sulfonate (PFOS)},
journal = {Environmental Pollution},
year = {2024},
volume = {346},
pages = {123544},
doi = {10.1016/j.envpol.2024.123544}
}
EUVIMED